Cardio-oncology impact factor, indexing, ranking (2024)


cardio-oncology

Aim and Scope

The Cardio-oncology is a research journal that publishes research related to Medicine. This journal is published by the BioMed Central Ltd.. The ISSN of this journal is 20573804. Based on the Scopus data, the SCImago Journal Rank (SJR) of cardio-oncology is 0.79.

Also, please check the following important details about cardio-oncology: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

Cardio-oncology Ranking

Impact Factor: N/A
Total Citations: 196
SJR (SCImago Journal Rank): 0.79
Quartile: Q2

The Impact Factor of Cardio-oncology is N/A.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times its articles are cited.

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Impact factors began to be calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson-Reuters spun off and sold ISI to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.


Important Metrics

Journal Title: Cardio-Oncology
Publisher: BioMed Central Ltd.
ISSN: 20573804
Type: journal
Journal Scope: Medicine
Country: United Kingdom
H-Index: 17
SJR: 0.79
Quartile: Cardiology and Cardiovascular Medicine (Q2); Oncology (Q2)

cardio-oncology Indexing

The cardio-oncology is indexed in:

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).

Note: ESCI journals donot come with an impact factor. However, ESCI journals are evaluated every year and those who qualified are transferred to SCIE.


Cardio-oncology Impact Factor 2024

The latest impact factor of cardio-oncology is N/A.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times it's articles are cited.

Note: Every year, The Clarivate releases the Journal Citation Report (JCR). The JCR provides information about academic journals including impact factor. The latest JCR was released in June, 2023. The JCR 2024 will be released in the June 2024.


Cardio-oncology Quartile

The latest Quartile of cardio-oncology is Q2.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.


Publication fee

According to journal website, the publication fee of cardio-oncology is around 2090 EUR; 2490 USD; 1690 GBP.

The cardio-oncology has also Journal waiver policy (for developing countries, authors etc).

An article processing charge (APC), also known as a publication fee, is a fee which is sometimes charged to authors. Most commonly, it is involved in making a work available as open access (OA), in either a full OA journal or in a hybrid journal.



Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Cardio-oncology?

If your research is related to Medicine, then visit the official website of cardio-oncology and send your manuscript.

Tips for publishing in Cardio-oncology:

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Journal Publication Time

The Journal Publication Time means the average number of weeks between article submission and publication. According to the journal website, the cardio-oncology publishes research articles in 7 weeks on an average.


Final Summary

  • The impact factor of cardio-oncology is N/A.
  • The cardio-oncology is a reputed research journal.
  • It is published by BioMed Central Ltd..
  • The journal is indexed in UGC CARE, Scopus, ESCI, DOAJ, PubMed.
  • It is an open access journal.
  • The (SJR) SCImago Journal Rank is 0.79.
  • The publication time (Average number of weeks between article submission and publication) of the journal is 7 weeks.
  • The Publication fee (APC) cardio-oncology 2090 EUR; 2490 USD; 1690 GBP.

Sources: https://cardiooncologyjournal.biomedcentral.com/







SIMILIAR JOURNALS


DENTAL AND MEDICAL PROBLEMS

ISSN: 1644-387X
Publisher: WROCLAW MEDICAL UNIV

RESUSCITATION PLUS

ISSN: 2666-5204
Publisher: ELSEVIER

WORLD JOURNAL OF TRADITIONAL CHINESE MEDICINE

ISSN: 2311-8571
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONS

AMERICAN JOURNAL OF CHINESE MEDICINE

ISSN: 0192-415X
Publisher: WORLD SCIENTIFIC PUBL CO PTE LTD

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS

ISSN: 1350-6129
Publisher: TAYLOR & FRANCIS LTD

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

ISSN: 1084-9785
Publisher: MARY ANN LIEBERT, INC

CURRENT MEDICAL RESEARCH AND OPINION

ISSN: 0300-7995
Publisher: TAYLOR & FRANCIS LTD

DENTOMAXILLOFACIAL RADIOLOGY

ISSN: 0250-832X
Publisher: BRITISH INST RADIOLOGY

EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

ISSN: 0014-2972
Publisher: WILEY

INDIAN JOURNAL OF MEDICAL RESEARCH

ISSN: 0971-5916
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONS

TOP RESEARCH JOURNALS

Credit and Source: Scopus, Clarivate, UGC CARE.